ATM is altered in 5.76% of prostate carcinoma patients with ATM Mutation present in 5.03% of all prostate carcinoma patients [4].

ATM Mutation is an inclusion criterion in 22 clinical trials for prostate carcinoma, of which 19 are open and 3 are closed. Of the trials that contain ATM Mutation and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 13 are phase 2 (12 open), and 2 are phase 3 (2 open) [5].

Olaparib has evidence of efficacy in patients with ATM Mutation in prostate carcinoma [5].

ATM is altered in 5.8% of malignant solid tumor patients with ATM Mutation present in 5.37% of all malignant solid tumor patients [4].

ATM Mutation is an inclusion criterion in 41 clinical trials for malignant solid tumor, of which 34 are open and 7 are closed. Of the trials that contain ATM Mutation and malignant solid tumor as inclusion criteria, 15 are phase 1 (11 open), 7 are phase 1/phase 2 (4 open), and 19 are phase 2 (19 open) [5].

ATM is altered in 3.53% of breast carcinoma patients with ATM Mutation present in 3.08% of all breast carcinoma patients [4].

ATM Mutation is an inclusion criterion in 22 clinical trials for breast carcinoma, of which 17 are open and 5 are closed. Of the trials that contain ATM Mutation and breast carcinoma as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 11 are phase 2 (9 open), and 2 are phase 3 (2 open) [5].

ATM is altered in 4.06% of ovarian carcinoma patients with ATM Mutation present in 3.64% of all ovarian carcinoma patients [4].

ATM Mutation is an inclusion criterion in 19 clinical trials for ovarian carcinoma, of which 14 are open and 5 are closed. Of the trials that contain ATM Mutation and ovarian carcinoma as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 8 are phase 2 (7 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

ATM is altered in 5.73% of prostate adenocarcinoma patients with ATM Mutation present in 5.02% of all prostate adenocarcinoma patients [4].

ATM Mutation is an inclusion criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain ATM Mutation and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [5].

ATM is altered in 4.35% of primary peritoneal carcinoma patients with ATM Mutation present in 4.35% of all primary peritoneal carcinoma patients [4].

ATM Mutation is an inclusion criterion in 9 clinical trials for primary peritoneal carcinoma, of which 6 are open and 3 are closed. Of the trials that contain ATM Mutation and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

ATM is altered in 7.14% of non-small cell lung carcinoma patients with ATM Mutation present in 6.66% of all non-small cell lung carcinoma patients [4].

ATM Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 6 are open and 2 are closed. Of the trials that contain ATM Mutation and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].

ATM is altered in 5.26% of adenocarcinoma of the gastroesophageal junction patients with ATM Mutation present in 5.26% of all adenocarcinoma of the gastroesophageal junction patients [4].

ATM Mutation is an inclusion criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain ATM Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [5].

ATM Mutation is an inclusion criterion in 8 clinical trials for fallopian tube carcinoma, of which 5 are open and 3 are closed. Of the trials that contain ATM Mutation and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

ATM is altered in 4.2% of pancreatic adenocarcinoma patients with ATM Mutation present in 3.9% of all pancreatic adenocarcinoma patients [4].

ATM Mutation is an inclusion criterion in 7 clinical trials for pancreatic adenocarcinoma, of which 6 are open and 1 is closed. Of the trials that contain ATM Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [5].

ATM is altered in 10.7% of urothelial carcinoma patients with ATM Mutation present in 10.33% of all urothelial carcinoma patients [4].

ATM Mutation is an inclusion criterion in 6 clinical trials for urothelial carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ATM Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 5 are phase 2 (5 open) [5].

ATM is altered in 4.18% of pancreatic carcinoma patients with ATM Mutation present in 3.89% of all pancreatic carcinoma patients [4].

ATM Mutation is an inclusion criterion in 6 clinical trials for pancreatic carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ATM Mutation and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (4 open) [5].

ATM is altered in 7.51% of colorectal carcinoma patients with ATM Mutation present in 7.14% of all colorectal carcinoma patients [4].

ATM Mutation is an inclusion criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ATM Mutation and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

ATM is altered in 6.99% of gastric carcinoma patients with ATM Mutation present in 6.34% of all gastric carcinoma patients [4].

ATM Mutation is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain ATM Mutation and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

ATM is altered in 6.87% of melanoma patients with ATM Mutation present in 6.17% of all melanoma patients [4].

ATM Mutation is an inclusion criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain ATM Mutation and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [5].

ATM is altered in 11.39% of endometrial carcinoma patients with ATM Mutation present in 10.92% of all endometrial carcinoma patients [4].

ATM Mutation is an inclusion criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ATM Mutation and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

ATM is altered in 7.97% of non-hodgkin lymphoma patients with ATM Mutation present in 7.12% of all non-hodgkin lymphoma patients [4].

ATM Mutation is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain ATM Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].

ATM is altered in 6.84% of gastric adenocarcinoma patients with ATM Mutation present in 6.17% of all gastric adenocarcinoma patients [4].

ATM Mutation is an inclusion criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain ATM Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [5].

ATM is altered in 5.29% of cervical carcinoma patients with ATM Mutation present in 5.11% of all cervical carcinoma patients [4].

ATM Mutation is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATM Mutation and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

ATM is altered in 4.14% of head and neck carcinoma patients with ATM Mutation present in 4.05% of all head and neck carcinoma patients [4].

ATM Mutation is an inclusion criterion in 4 clinical trials for head and neck carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATM Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

ATM is altered in 3.75% of small cell lung carcinoma patients with ATM Mutation present in 3.37% of all small cell lung carcinoma patients [4].

ATM Mutation is an inclusion criterion in 4 clinical trials for small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATM Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [5].

ATM is altered in 2.52% of soft tissue sarcoma patients with ATM Mutation present in 2.13% of all soft tissue sarcoma patients [4].

ATM Mutation is an inclusion criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain ATM Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

ATM is altered in 10.67% of bladder carcinoma patients with ATM Mutation present in 10.38% of all bladder carcinoma patients [4].

ATM Mutation is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ATM Mutation and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

ATM is altered in 4.43% of clear cell renal cell carcinoma patients with ATM Mutation present in 4.43% of all clear cell renal cell carcinoma patients [4].

ATM Mutation is an inclusion criterion in 3 clinical trials for clear cell renal cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ATM Mutation and clear cell renal cell carcinoma as inclusion criteria, 3 are phase 2 (3 open) [5].

ATM is altered in 3.61% of high grade ovarian serous adenocarcinoma patients with ATM Mutation present in 3.13% of all high grade ovarian serous adenocarcinoma patients [4].

ATM Mutation is an inclusion criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain ATM Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

ATM is altered in 11.08% of bladder urothelial carcinoma patients with ATM Mutation present in 10.77% of all bladder urothelial carcinoma patients [4].

ATM Mutation is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATM Mutation and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ATM is altered in 6.6% of lymphoma patients with ATM Mutation present in 5.96% of all lymphoma patients [4].

ATM Mutation is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ATM Mutation and lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

ATM is altered in 4.98% of squamous cell lung carcinoma patients with ATM Mutation present in 4.66% of all squamous cell lung carcinoma patients [4].

ATM Mutation is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATM Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [5].

ATM is altered in 4.45% of head and neck squamous cell carcinoma patients with ATM Mutation present in 4.38% of all head and neck squamous cell carcinoma patients [4].

ATM Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATM Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

ATM is altered in 4.49% of malignant central nervous system neoplasm patients with ATM Mutation present in 4.26% of all malignant central nervous system neoplasm patients [4].

ATM Mutation is an inclusion criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ATM Mutation and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

ATM is altered in 4.55% of multiple myeloma patients with ATM Mutation present in 4.13% of all multiple myeloma patients [4].

ATM Mutation is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain ATM Mutation and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [5].

ATM is altered in 3.87% of esophageal carcinoma patients with ATM Mutation present in 3.47% of all esophageal carcinoma patients [4].

ATM Mutation is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATM Mutation and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

ATM is altered in 3.9% of esophageal adenocarcinoma patients with ATM Mutation present in 3.41% of all esophageal adenocarcinoma patients [4].

ATM Mutation is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATM Mutation and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

ATM is altered in 2.42% of osteosarcoma patients with ATM Mutation present in 2.08% of all osteosarcoma patients [4].

ATM Mutation is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain ATM Mutation and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

ATM is altered in 2.49% of gastrointestinal stromal tumor patients with ATM Mutation present in 1.95% of all gastrointestinal stromal tumor patients [4].

ATM Mutation is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain ATM Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

ATM is altered in 41.9% of mantle cell lymphoma patients with ATM Mutation present in 38.55% of all mantle cell lymphoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ATM is altered in 41.67% of prolymphocytic leukemia patients with ATM Mutation present in 33.33% of all prolymphocytic leukemia patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for prolymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 14.29% of vaginal carcinoma patients with ATM Mutation present in 14.29% of all vaginal carcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATM Mutation and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ATM is altered in 13.68% of malignant small intestinal neoplasm patients with ATM Mutation present in 12.63% of all malignant small intestinal neoplasm patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ATM is altered in 8.86% of malignant uterine neoplasm patients with ATM Mutation present in 8.48% of all malignant uterine neoplasm patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 8.97% of B-cell non-hodgkin lymphoma patients with ATM Mutation present in 8.03% of all B-cell non-hodgkin lymphoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 7.7% of malignant intestinal neoplasm patients with ATM Mutation present in 7.31% of all malignant intestinal neoplasm patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ATM is altered in 7.49% of colorectal adenocarcinoma patients with ATM Mutation present in 7.11% of all colorectal adenocarcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ATM is altered in 7.0% of lung carcinoma patients with ATM Mutation present in 6.52% of all lung carcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 6.99% of malignant gastric neoplasm patients with ATM Mutation present in 6.34% of all malignant gastric neoplasm patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ATM is altered in 6.07% of gallbladder carcinoma patients with ATM Mutation present in 5.71% of all gallbladder carcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 5.71% of pancreatic ductal adenocarcinoma patients with ATM Mutation present in 5.71% of all pancreatic ductal adenocarcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATM Mutation and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

ATM is altered in 6.18% of ampulla of vater carcinoma patients with ATM Mutation present in 5.62% of all ampulla of vater carcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ATM is altered in 5.46% of medulloblastoma patients with ATM Mutation present in 5.46% of all medulloblastoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ATM is altered in 5.88% of biliary tract carcinoma patients with ATM Mutation present in 5.44% of all biliary tract carcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 5.83% of bile duct adenocarcinoma patients with ATM Mutation present in 5.36% of all bile duct adenocarcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ATM is altered in 5.83% of bile duct carcinoma patients with ATM Mutation present in 5.36% of all bile duct carcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 5.83% of cholangiocarcinoma patients with ATM Mutation present in 5.36% of all cholangiocarcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 5.67% of cancer patients with ATM Mutation present in 5.25% of all cancer patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and cancer as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 5.35% of malignant esophagogastric neoplasm patients with ATM Mutation present in 4.91% of all malignant esophagogastric neoplasm patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ATM is altered in 5.15% of glioblastoma patients with ATM Mutation present in 4.83% of all glioblastoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ATM Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ATM is altered in 4.54% of renal cell carcinoma patients with ATM Mutation present in 4.41% of all renal cell carcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 4.59% of malignant mesothelioma patients with ATM Mutation present in 4.32% of all malignant mesothelioma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 4.54% of glioma patients with ATM Mutation present in 4.3% of all glioma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

ATM is altered in 4.64% of mature T-cell and NK-cell non-hodgkin lymphoma patients with ATM Mutation present in 4.06% of all mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ATM is altered in 4.48% of anal carcinoma patients with ATM Mutation present in 3.98% of all anal carcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATM Mutation and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ATM is altered in 4.23% of malignant ovarian epithelial tumor patients with ATM Mutation present in 3.83% of all malignant ovarian epithelial tumor patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ATM is altered in 4.01% of leiomyosarcoma patients with ATM Mutation present in 3.71% of all leiomyosarcoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 3.57% of penile carcinoma patients with ATM Mutation present in 3.57% of all penile carcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATM Mutation and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ATM is altered in 3.38% of esophageal squamous cell carcinoma patients with ATM Mutation present in 3.38% of all esophageal squamous cell carcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 3.77% of diffuse large B-cell lymphoma patients with ATM Mutation present in 3.21% of all diffuse large B-cell lymphoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ATM is altered in 3.02% of anaplastic astrocytoma patients with ATM Mutation present in 3.02% of all anaplastic astrocytoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains ATM Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ATM is altered in 3.44% of invasive breast carcinoma patients with ATM Mutation present in 2.98% of all invasive breast carcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 2.97% of sarcoma patients with ATM Mutation present in 2.57% of all sarcoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ATM Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ATM is altered in 2.39% of low grade ovarian serous adenocarcinoma patients with ATM Mutation present in 1.91% of all low grade ovarian serous adenocarcinoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ATM is altered in 1.93% of myelodysplastic syndromes patients with ATM Mutation present in 1.8% of all myelodysplastic syndromes patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 1.87% of acute myeloid leukemia patients with ATM Mutation present in 1.74% of all acute myeloid leukemia patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 3.2% of neuroblastoma patients with ATM Mutation present in 1.33% of all neuroblastoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ATM is altered in 1.23% of chronic myeloid leukemia patients with ATM Mutation present in 1.23% of all chronic myeloid leukemia patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and chronic myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 1.06% of langerhans cell histiocytosis patients with ATM Mutation present in 1.06% of all langerhans cell histiocytosis patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for langerhans cell histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and langerhans cell histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM is altered in 0.49% of rhabdomyosarcoma patients with ATM Mutation present in 0.49% of all rhabdomyosarcoma patients [4].

ATM Mutation is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ATM Mutation is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM Mutation is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM Mutation is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM Mutation is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ATM Mutation is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ATM Mutation is an inclusion criterion in 1 clinical trial for histiocytic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and histiocytic sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM Mutation is an inclusion criterion in 1 clinical trial for juvenile xanthogranuloma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and juvenile xanthogranuloma as inclusion criteria, 1 is phase 2 (1 open) [5].

ATM Mutation is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ATM Mutation is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM Mutation and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ATM Mutation is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATM Mutation and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].